Radiosensitization of HT-29 cells and xenografts by the nitric oxide donor DETANONOate

Journal of Surgical Oncology

Volumn 100, Issue 2, 2009, Pages 149-158

  Gao, Xiaohuan ^a   Saha, Debabrata ^a   Kapur, Payal ^a   Anthony, Thomas ^a   Livingston, Edward H ^a   Huerta, Sergio ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Surgical Services (112)   (United States)

Author keywords

BAX; Bcl 2; p21; p27; PARP 1

Indexed keywords

1 [N (2 AMINOETHYL) N (2 AMMONIOETHYL)AMINO]DIAZEN 1 IUM 1,2 DIOLIC ACID; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NITRIC OXIDE DONOR; P21 ACTIVATED KINASE; PROTEIN BAX; PROTEIN BCL 2; RADIOSENSITIZING AGENT; SURVIVIN; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CLONOGENIC ASSAY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; RECTUM CANCER; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; BCL-2-ASSOCIATED X PROTEIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HCT116 CELLS; HT29 CELLS; HUMANS; MICE; MICE, SCID; MICROTUBULE-ASSOCIATED PROTEINS; NITRIC OXIDE DONORS; NITROSO COMPOUNDS; RADIATION-SENSITIZING AGENTS; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67749086634     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21318     Document Type: Article

References (60)

1. Jemal A, Siegel R,Ward E, et al.: Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Ahmad NR, Nagle D: Long-term results of preoperative radiation therapy alone for stage T3 and T4 rectal cancer. Br J Surg 1997;84:1445-1448. (Pubitemid 27443455)
3. Wanebo HJ, Koness RJ, Vezeridis MP, et al.: Pelvic resection of recurrent rectal cancer. Ann Surg 1994;220:586-595.
4. Chari RS, Tyler DS, Anscher MS, et al.: Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum. Ann Surg 1995;221:778-786.
5. Morino M, Parini U, Allaix ME, et al.: Male sexual and urinary function after laparoscopic total mesorectal excision. Surg Endosc 2008. [Epub ahead of print. PMID 18855065]
6. Rodel C, Sauer R: Radiotherapy and concurrent radiochemotherapy for rectal cancer. Surg Oncol 2004;13:93-101. (Pubitemid 39572083)
7. Carraro S, Roca EL, Cartelli C, et al.: Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: A phase II IATTGI study. Int J Radiat Oncol Biol Phys 2002;54:397-402. (Pubitemid 35286803)
8. Dunst J, Reese T, Sutter T, et al.: Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 2002;20:3983-3991.
9. Gerard A, Buyse M, Nordlinger B, et al.: Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC). Ann Surg 1988;208:606-614.
10. Krishnan S, Janjan NA, Skibber JM, et al.: Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2006;66:762-771. (Pubitemid 44436703)
11. Willeke F, Horisberger K, Kraus-Tiefenbacher U, et al.: A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT)as neoadjuvant treatment of locally advanced rectal cancer. Br J Cancer 2007;96:912-917. (Pubitemid 46452282)
12. Lowe SW, Schmitt EM, Smith SW, et al.: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993;362:847-849. (Pubitemid 23132161)
13. Waldman T, Lengauer C, Kinzler KW, et al.: Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 1996;381:713-716. (Pubitemid 26196573)
14. Esposito G, Pucciarelli S, Alaggio R, et al.: P27kip1 expression is associated with tumor response to preoperative chemoradiotherapy in rectal cancer. Ann Surg Oncol 2001;8:311-318. (Pubitemid 32422856)
15. Russo SM, Tepper JE, Baldwin AS, Jr., , et al.: Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 2001;50:183-193.
16. Rodel F, Frey B, Leitmann W, et al.: Survivin antisense oligonucleotides effectively radiosensitize colorectal cancer cells in both tissue culture and murine xenograft models. Int J Radiat Oncol Biol Phys 2008;71:247-255.
17. Bhatavdekar JM, PatelDD,Ghosh N, et al.: Coexpression of Bcl-2, c -Myc, and p53 oncoproteins as prognostic discriminants in patients with colorectal carcinoma. Dis Colon Rectum 1997;40:785-790.
18. Meyn RE, Stephens LC, Milas L: Programmed cell death and radioresistance. Cancer Metastasis Rev 1996;15:119-131.
19. Bilir A, Erguven M, Oktem G, et al.: Potentiation of cytotoxicity by combination of imatinib and chlorimipramine in glioma. Int J Oncol 2008;32:829-839. (Pubitemid 351780593)
20. Bonavida B, Huerta-Yepez S, Goodglick L, et al.: Can we develop biomarkers that predict response of cancer patients to immunotherapy? Biomarkers 2005;10:S69-S76.
21. Garban HJ, Bonavida B: Nitric oxide sensitizes ovarian tumor cells to Fas-induced apoptosis. Gynecol Oncol 1999;73:257-264. (Pubitemid 29215741)
22. Huerta-Yepez S, Vega M, Jazirehi A, et al.: Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression. Oncogene 2004;23:4993-5003. (Pubitemid 38938732)
23. Huerta S, Baay-Guzman G, Gonzalez-Bonilla CR, et al.: In vitro and in vivo sensitization of SW620 metastatic colon cancer cells to CDDP-induced apoptosis by the nitric oxide donor DETANONOate: Involvement of AIF. Nitric Oxide 2008;20:182-194.
24. Bonavida B, Khineche S, Huerta-Yepez S, et al.: Therapeutic potential of nitric oxide in cancer. Drug Resist Updat 2006;9:157-173. (Pubitemid 44294871)
25. Huerta S, Chilka S, Bonavida B: Nitric oxide donors: Novel cancer therapeutics (review). Int J Oncol 2008;33:909-927.
26. Huerta S, Harris DM, Jazirehi A, et al.: Gene expression profile of metastatic colon cancer cells resistant to cisplatin-induced apoptosis. Int J Oncol 2003;22:663-670.
27. Huerta S, Heinzerling JH, Anguiano-Hernandez YM, et al.: Modi- fication of gene products involved in resistance to apoptosis in metastatic colon cancer cells: Roles of Fas, Apaf-1, NFkappaB, IAPs, Smac/DIABLO, and AIF. J Surg Res 2007;142:184-194. (Pubitemid 47277413)
28. Voland C, Bord A, Peleraux A, et al.: Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells. Mol Cancer Ther 2006;5:2149-2157. (Pubitemid 44530450)
29. Shibata D, Peinado MA, Ionov Y, et al.: Genomic instability in repeated sequences is an early somatic event in colorectal tumorigenesis that persists after transformation. Nat Genet 1994;6:273-281. (Pubitemid 24188625)
30. Kim JC, Saha D, Cao Q, et al.: Enhancement of radiation effects by combined docetaxel and flavopiridol treatment in lung cancer cells. Radiother Oncol 2004;71:213-221. (Pubitemid 38521191)
31. Wong RK, Tandan V, De SS, et al.: Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. Cochrane Database Syst Rev 2007;CD002102.
32. Mohiuddin M, Winter K, Mitchell E, et al.: Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol 2006;24:650-655. (Pubitemid 46630429)
33. Lowe SW, Schmitt EM, Smith SW, et al.: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993;362:847-849. (Pubitemid 23132161)
34. Bracey TS, Miller JC, Preece A, et al.: Gamma-radiation-induced apoptosis inhuman colorectal adenoma and carcinoma cell lines can occur in the absence of wild type p53. Oncogene 1995;10:2391-2396.
35. Merritt AJ, Potten CS, Kemp CJ, et al.: The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res 1994;54:614-617.
36. Spitz FR, Nguyen D, Skibber JM, et al.: Adenoviral-mediated wildtype p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin Cancer Res 1996;2:1665-1671. (Pubitemid 26356349)
37. Hendry JH, Cai WB, Roberts SA, et al.: p53 deficiency sensitizes clonogenic cells to irradiation in the large but not the small intestine. Radiat Res 1997;148:254-259.
38. Slichenmyer WJ, Nelson WG, Slebos RJ, et al.: Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res 1993;53:4164-4168.
39. Ribeiro JC, Barnetson AR, Fisher RJ, et al.: Relationship between radiation response and p53 status inhuman bladder cancer cells. Int J Radiat Biol 1997;72:11-20.
40. Namba H, Hara T, Tukazaki T, et al.: Radiation-induced G1 arrest is selectively mediated by the p53-WAF1/Cip1 pathway in human thyroid cells. Cancer Res 1995;55:2075-2080.
41. el-Deiry WS, Tokino T, Velculescu VE, et al.: WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-825.
42. Waldman T, Lengauer C, Kinzler KW, et al.: Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 1996;381:713-716. (Pubitemid 26196573)
43. Brugarolas J, Chandrasekaran C, Gordon JI, et al.: Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995;377:552-557.
44. Waldman T, Zhang Y, Dillehay L, et al.: Cell-cycle arrest versus cell death in cancer therapy. Nat Med 1997;3:1034-1036. (Pubitemid 27391962)
45. Tian H, Wittmack EK, Jorgensen TJ: p21WAF1/CIP1 antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis. Cancer Res 2000;60:679-684. (Pubitemid 30094567)
46. Chipuk JE, Kuwana T, Bouchier-Hayes L, et al.: Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004;303:1010-1014. (Pubitemid 38209704)
47. Huerta S, Goulet EJ, Huerta-Yepez S, et al.: Screening and detection of apoptosis. J Surg Res 2007;139:143-156.
48. Sinicrope FA, Ruan SB, Cleary KR, et al.: bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 1995;55:237-241.
49. Bhatavdekar JM, PatelDD,GhoshN, et al.: Coexpression of Bcl-2, c -Myc, and p53 oncoproteins as prognostic discriminants in patients with colorectal carcinoma. Dis Colon Rectum 1997;40:785-790.
50. LaCasse EC, Baird S, Korneluk RG, et al.: The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998;17:3247-3259. (Pubitemid 29043977)
51. Verhagen AM, Vaux DL: Cell death regulation by the mammalian IAP antagonist Diablo/Smac. Apoptosis 2002;7:163-166.
52. Rodel F, Hoffmann J, Grabenbauer GG, et al.: High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol 2002;178:426-435. (Pubitemid 34847422)
53. Rodel F, Hoffmann J, Distel L, et al.: Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005;65:4881-4887. (Pubitemid 40740827)
54. Rodel F, Frey B, Leitmann W, et al.: Survivin antisense oligonucleotides effectively radiosensitize colorectal cancer cells in both tissue culture and murine xenograft models. Int J Radiat Oncol Biol Phys 2008;71:247-255.
55. Howard-Flanders P: Effect of nitric oxide on the radiosensitivity of bacteria. Nature 1957;180:1191-1192.
56. Mitchell JB, Cook JA, Krishna MC, et al.: Radiation sensitisation by nitric oxide releasing agents. Br J Cancer Suppl 1996;27:S181-S184. (Pubitemid 26237957)
57. Janssens MY, Van den Berge DL, Verovski VN, et al.: Activation of inducible nitric oxide synthase results in nitric oxide-mediated radiosensitization of hypoxic EMT-6 tumor cells. Cancer Res 1998;58:5646-5648.
58. Dejardin E, Deregowski V, Chapelier M, et al.: Regulation of NFkappaB activity by I kappaB-related proteins in adenocarcinoma cells. Oncogene 1999;18:2567-2577. (Pubitemid 29216679)
59. Taylor AL, Ziesche S, Yancy C, et al.: Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049-2057. (Pubitemid 39482498)
60. Yasuda H, Yamaya M, Nakayama K, et al.: Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2006;24:688-694. (Pubitemid 46630435)